{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:14:26Z","timestamp":1752549266097},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,28]]},"DOI":"10.7759\/cureus.10098","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T18:07:53Z","timestamp":1598638073000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Report on Adult-Onset Still\u2019s Disease Successfully Treated With Tocilizumab: A Brief Review on its Safety and Efficacy"],"prefix":"10.7759","author":[{"given":"Shivaraj","family":"Nagalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Shankar Kikkeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasef","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2019s disease in the adult","volume":"30","author":"Bywaters EG","year":"1971","unstructured":"Bywaters EG. Still\u2019s disease in the adult. Ann Rheum Dis. 1971, 30:121-133. 10.1136\/ard.30.2.121","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still's disease: advances in the treatment","volume":"30","author":"Castan\u0303eda S","year":"2016","unstructured":"Castan\u0303eda S, Blanco R, Gonza\u0301lez-Gay MA. Adult-onset Still's disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016, 30:222-238. 10.1016\/j.berh.2016.08.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko Y","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, et al.. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018, 77:1720-1729. 10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease","volume":"7","author":"Li T","year":"2017","unstructured":"Li T, Gu L, Wang X, Guo L, Shi H, Yang C, Chen S. A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep. 2017, 7:13477. 10.1038\/s41598-017-13639-y","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel B","year":"2008","unstructured":"Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008, 22:773-792. 10.1016\/j.berh.2008.08.006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","article-title":"Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease","volume":"25","author":"Hoshino T","year":"1998","unstructured":"Hoshino T, Ohta A, Yang D, et al.. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol. 1998, 25:396-398.","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease","volume":"40","author":"Fujii T","year":"2001","unstructured":"Fujii T, Nojima T, Yasuoka H, et al.. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology. 2001, 40:1398-1404. 10.1093\/rheumatology\/40.12.1398","journal-title":"Rheumatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanjuan\u0301 F","year":"2015","unstructured":"Ortiz-Sanjuan\u0301 F, Blanco R, Riancho-Zarrabeitia L, et al.. Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review. Medicine. 2015, 94:e1554. 10.1097\/MD.0000000000001554","journal-title":"Medicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.2.144","article-title":"Methotrexate treatment in patients with adult onset Still's disease--retrospective study of 13 Japanese cases","volume":"56","author":"Fujii T","year":"1997","unstructured":"Fujii T, Akizuki M, Kameda H, et al.. Methotrexate treatment in patients with adult onset Still's disease--retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997, 56:144-148. 10.1136\/ard.56.2.144","journal-title":"Ann Rheum Dis"},{"key":"ref10","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel B","year":"1999","unstructured":"Fautrel B, Borget C, Rozenberg S, et al.. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol. 1999, 26:373-378.","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study","volume":"25","author":"Nishina N","year":"2015","unstructured":"Nishina N, Kaneko Y, Kameda H, Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study. Mod Rheumatol. 2015, 25:401-404. 10.3109\/14397595.2014.973659","journal-title":"Mod Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.042945","article-title":"Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?","volume":"64","author":"Aarntzen EH","year":"2005","unstructured":"Aarntzen EH, van Riel PL, Barrera P. Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?. Ann Rheum Dis. 2005, 64:1523-1524. 10.1136\/ard.2005.042945","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologics for the treatment of adult-onset still\u2019s disease","volume":"19","author":"Yoo DH","year":"2019","unstructured":"Yoo DH. Biologics for the treatment of adult-onset still\u2019s disease.  Expert Opin Biol Ther. 2019, 19:1173-1190. 10.1080\/14712598.2019.1652591","journal-title":"Expert Opin Biol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Pu\u00e9chal X","year":"2011","unstructured":"Pu\u00e9chal X, DeBandt M, Berthelot JM, et al.. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011, 63:155-159. 10.1002\/acr.20319","journal-title":"Arthritis Care Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-003-0775-5","article-title":"Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients","volume":"23","author":"Kokkinos A","year":"2004","unstructured":"Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004, 23:45-49. 10.1007\/s10067-003-0775-5","journal-title":"Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.03.004","article-title":"The use of canakinumab, a novel IL-1b long-acting inhibitor, in refractory adult-onset Still\u2019s disease","volume":"42","author":"Kontzias A","year":"2012","unstructured":"Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1b long-acting inhibitor, in refractory adult-onset Still\u2019s disease. Semin Arthritis Rheum. 2012, 42:201-205. 10.1016\/j.semarthrit.2012.03.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-826865","article-title":"Longterm outcome of TNF blockade in adult-onset Still\u2019s disease","volume":"129","author":"Dechant C","year":"2004","unstructured":"Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B. Longterm outcome of TNF blockade in adult-onset Still\u2019s disease. Dtsch Med Wochenschr. 2004, 129:1308-1312. 10.1055\/s-2004-826865","journal-title":"Dtsch Med Wochenschr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy- resistant adult-onset Still's disease: an evidence-based review","volume":"14","author":"Zhou S","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H. Biological therapy of traditional therapy- resistant adult-onset Still's disease: an evidence-based review. Ther Clin Risk Manag. 2018, 14:167-171. 10.2147\/TCRM.S155488","journal-title":"Ther Clin Risk Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2105-2","article-title":"Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence","volume":"32","author":"de Boysson H","year":"2013","unstructured":"de Boysson H, F\u00e9vrier J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol. 2013, 32:141-147. 10.1007\/s10067-012-2105-2","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3299","article-title":"SAT0525 tocilizumab compared with anakinra in refractory adult-onset Still's disease","volume":"74","author":"Palmou N","year":"2015","unstructured":"Palmou N, Calvo-R\u00edo V, Blanco R, et al.. SAT0525 tocilizumab compared with anakinra in refractory adult-onset Still's disease. Ann Rheum Dis. 2015, 74:850. 10.1136\/annrheumdis-2015-eular.3299","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/40026-a-case-report-on-adult-onset-stills-disease-successfully-treated-with-tocilizumab-a-brief-review-on-its-safety-and-efficacy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:21:52Z","timestamp":1707506512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/40026-a-case-report-on-adult-onset-stills-disease-successfully-treated-with-tocilizumab-a-brief-review-on-its-safety-and-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.10098","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}